MARGetuximab Or Trastuzumab (MARGOT) A phase II study comparing neoadjuvant paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab in patients with Stage II-III HER2-positive breast cancer
The study is looking at two different treatments for HER-2 positive breast cancer. The study is all about comparing two groups of patients: Group 1: These patients will receive a combination of three medicines before their main treatment. The medicines are paclitaxel, margetuximab, and pertuzumab. These medicines are meant to shrink the cancer and slow its growth. Group 2: These patients will receive another combination of three medicines before their main treatment. The medicines are paclitaxel, trastuzumab, and pertuzumab. Trastuzumab is another medicine that targets the HER2 protein. This treatment happens before their main treatment, and it's called neoadjuvant treatment. The main goal is to see if the combination of medicines in Group 1 (with margetuximab) works better at treating the cancer compared to the combination in Group 2 (with trastuzumab). The patients in the study have Stage II-III breast cancer, which means the cancer has grown but hasn't spread all over the body.
HER-2 Positive: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.
For more information about the trial, click the link below:
Clinical Trial Site: Einstein
To see all available clinical trials click here.